Xpovio FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved July 3, 2019)
Brand name: Xpovio
Generic name: selinexor
Dosage form: Tablets
Company: Karyopharm Therapeutics Inc.
Treatment for: Multiple Myeloma; Diffuse Large B-cell Lymphoma
Xpovio (selinexor) is a first in class Selective Inhibitor of Nuclear Export (SINE) XPO1 antagonist for the treatment of patients adult patients with multiple myeloma (RRMM) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Indications
- Multiple Myeloma
- In combination with bortezomib and dexamethasone for the treatment of
adult patients with multiple myeloma who have received at least one prior therapy.
- In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
- Diffuse Large B-Cell Lymphoma
- For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
These indications are approved under accelerated approval based on
response rate. Continued approval for these indications may be contingent
upon verification and description of clinical benefit in confirmatory trials.
Development timeline for Xpovio
| Date | Article |
|---|
| Jun 3, 2021 | Karyopharm Announces Xpovio (selinexor) Is Now Available in Additional Strength Tablets |
| Dec 18, 2020 | Approval Karyopharm Announces FDA Approval of Xpovio (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy |
| Jun 22, 2020 | Approval Karyopharm Announces FDA Approval of Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
| Jul 3, 2019 | Approval FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma |
| Mar 14, 2019 | Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application |
| Feb 27, 2019 | Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma |
| Dec 1, 2018 | Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting |
| Nov 7, 2018 | Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma |
| Oct 5, 2018 | U.S. FDA Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review |
| Sep 13, 2018 | Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting |
| Aug 28, 2018 | Karyopharm to Present Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma at the Society of Hematologic Oncology 2018 Annual Meeting |
| Jul 18, 2018 | Karyopharm Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma |
| Apr 30, 2018 | Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma |
| Apr 10, 2018 | Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
